معرفی
Associate Professor Bing Wang is a world-leading researcher at the Baker Heart and Diabetes Institute, specializing in heart failure, cardiorenal syndrome, and biomarker discovery. With expertise in molecular cell biology, protein biochemistry, and drug development, he leads the Biomarker Discovery laboratory, bridging academic and biotechnology sectors to advance therapies for cardiovascular and renal diseases.
- BSc, Xiamen University
- MSc, Fujian Normal University
- PhD, La Trobe University
His research focuses on:
- Pathological mechanisms of inflammatory cytokines in cardiovascular diseases
- Development of novel therapeutics targeting HFpEF and cardiorenal syndrome
- Biomarker identification for early diagnosis and drug targets
- Pharmacological modulation of sphingolipid pathways in cardiac fibrosis
- Translational models bridging bench-to-clinic
Recent publications highlight his work on:
- Hypertension-induced cardiac aging
- Liver-heart crosstalk in HFpEF
- SGLT2 inhibitors for cardiac remodeling
- CD14 and CXCR7 inhibition in fibrosis
- Maternal multiparity's cardiovascular impacts
Scientific achievements include:
- La Trobe University Postgraduate Scholarship
- High Blood Pressure Council of Australia Young Investigator Award
Active grants from NHMRC, MRFF, and National Heart Fund support his work on drug development and biomarker validation. His lab's translational focus integrates preclinical models with clinical trials (e.g., RESTORE trial for knee osteoarthritis) to address unmet clinical needs in cardiorenal disorders.
